TONIX PHARMACEUTICALS HOLDING CORP. (TNXP)

Every figure this model derived for TNXP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 5,115,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 192,808,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 203,432,000 AssetsCurrent 2026-06-30
current liabilities 30,785,000 LiabilitiesCurrent 2026-06-30
equity 222,281,000 StockholdersEquity 2026-06-30
interest expense 89,000 InterestPaidNet 2025-12-31
ocf -152,993,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 29,102,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 7,938,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TNXP on one particular measure came for.

RatioValue
cash operating margin-533.86
current ratio7.54
current ratio reported6.61
deferred revenue growth26.9
dilution pct1057.84
fcf margin-543.29
interest cover-1858.71
operating margin-568.43
owner earnings margin-570.57
revenue growth196.02
revenue growth per share-74.43
roic-443.41
rule of 40-372.41
sbc pct revenue27.28

What to be careful about

What this model itself distrusts about TNXP's figures. Written by the derivation as it ran, not added afterwards.